Biolexis Therapeutics is a privately held biopharmaceutical company committed to developing novel targeted therapeutics.
Biolexis Therapeutics has raised $1.6M in total funding. The most recent round was Convertible Note. The last funding was announced in June 2026.
Biolexis Therapeutics's investors include Clarke Capital Partners.
Biolexis Therapeutics is headquartered in American Fork, United States.
Biolexis Therapeutics is a privately held biopharmaceutical company committed to developing novel targeted therapeutics.
Biolexis Therapeutics is at the Convertible Note stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Biolexis Therapeutics — Funding & Investors." VCBacked, June 3, 2026, https://www.vcbacked.co/company/biolexis-therapeutics. Accessed September 29, 2026.
VCBacked. (2026). Biolexis Therapeutics — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/biolexis-therapeutics
{{cite web |title=Biolexis Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/biolexis-therapeutics |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated